Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
Andreas E KremerMarlyn J MayoGideon M HirschfieldCynthia LevyChristopher L BowlusDavid E JonesJeff D JohnsonCharles A McWherterYun-Jung ChoiPublished in: Hepatology (Baltimore, Md.) (2023)
Seladelpar decreased serum IL-31 and bile acids in PBC patients. The reductions of IL-31 and bile acids correlated closely with each other and pruritus improvement suggesting a mechanism to explain seladelpar's anti-pruritic effects.